Angiogenesis protein therapy with human fibroblast growth factor (fgf-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG

被引：0
|
作者：
Wagoner, Lynne E. [1 ]
Merrill, Walter [1 ]
Jacobs, Jack [2 ]
Conway, Ginger [1 ]
Boehmer, John [3 ]
Thomas, Kenneth [2 ]
Stegmann, Thomas [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] CVBT, Las Vegas, NV USA
[3] Hershey Med Ctr, Hershey, PA USA
来源：
CIRCULATION | 2007年 / 116卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：443 / 443
页数：1
相关论文
共 50 条
  • [31] Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti-PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer
    Drescher, C.
    Moore, K. N.
    Liu, J. F.
    O'Malley, D. M.
    Wang, E. W.
    Wang, J. S-Z.
    Subbiah, V.
    Wilky, B. A.
    Yuan, G.
    Dupont, C. D.
    Gonzalez, A. M.
    Savitsky, D.
    Coulter, S.
    Shebanova, O.
    Dow, E.
    Ortuzar, W.
    Buell, J. S.
    Stein, R. B.
    Youssoufian, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [32] Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial
    Caballero, Iraida
    Aira, Lazaro E.
    Lavastida, Anabel
    Popa, Xitlally
    Rivero, Javier
    Gonzalez, Joaqun
    Mesa, Monica
    Gonzalez, Narjara
    Coba, Kelly
    Lorenzo-Luaces, Patricia
    Wilkinson, Barbara
    Santiesteban, Yuliannis
    Santiesteban, Yanela
    Troche, Mayelin
    Suarez, Eduardo
    Crombet, Tania
    Sanchez, Belinda
    Casaco, Angel
    Macias, Amparo
    Mazorra, Zaima
    FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [33] An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and I in a 4 week on, 2 week off schedule in patients with advanced solid tumors.
    Eskens, F. A.
    Planting, A.
    Van Doorn, L.
    Isoe, T.
    Hayashi, K.
    Hussain, S.
    Ekman, L.
    Burger, H.
    Verweij, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 87S - 87S
  • [34] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
    Xiaoxue Zhu
    Yanhua Ding
    Qian Wang
    Guiyu Yang
    Liang Zhou
    Qingyu Wang
    Investigational New Drugs, 2023, 41 : 473 - 482
  • [35] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
    Zhu, Xiaoxue
    Ding, Yanhua
    Wang, Qian
    Yang, Guiyu
    Zhou, Liang
    Wang, Qingyu
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 473 - 482
  • [36] A PHASE 1 OPEN LABEL DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAMUSCULAR HUMAN PLACENTA-DERIVED CELLS (PDA-002) IN SUBJECTS WHO HAVE DIABETIC FOOT ULCER (DFU) WITH PERIPHERAL ARTERY DISEASE (PAD)
    Wu, S.
    Pollak, R.
    Frykberg, R.
    Caporusso, J.
    Lawrence, P.
    Zhou, W.
    Rudinski, M.
    Karnoub, M.
    Chitkara, D.
    Fischkoff, S.
    WOUND REPAIR AND REGENERATION, 2015, 23 (02) : A45 - A45
  • [37] Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
    Ahn, Myung-Ju
    Han, Ji-Youn
    Lee, Ki Hyeong
    Kim, Sang-We
    Kim, Dong-Wan
    Lee, Yun-Gyoo
    Cho, Eun Kyung
    Kim, Joo-Hang
    Lee, Gyeong-Won
    Lee, Jong-Seok
    Min, Young Joo
    Kim, Jin-Soo
    Lee, Sung Sook
    Kim, Hye Ryun
    Hong, Min Hee
    Ahn, Jin Seok
    Sun, Jong-Mu
    Kim, Heung Tae
    Lee, Dae Ho
    Kim, Sohee
    Cho, Byoung Chul
    LANCET ONCOLOGY, 2019, 20 (12): : 1681 - 1690
  • [38] Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
    Janku, F.
    Abdul-Karim, R.
    Azad, A.
    Bendell, J.
    Gan, H.
    Sen, S.
    Tan, T.
    Wang, J.
    Marina, N.
    Baker, L.
    Ma, L.
    Mooney, J.
    Luo, D.
    Leveque, J.
    Milla, M.
    Meniawy, T.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S11 - S11
  • [39] A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL)
    Dickinson, Michael
    Kamdar, Manali
    Huntly, Brian J. P.
    Fernandez De larrea, Carlos
    Cordoba, Raul
    Mateos, Maria-Victoria
    Alegre, Adrian
    Kim, Won-Seog
    Kim, Jin Seok
    Dawson, Mark
    Yeh, Paul Sung-Hao
    Basheer, Faisal
    Gallipoli, Paolo
    Chaidos, Aristeidis
    Martin, Alejandro
    Horner, Thierry
    Winnberg, James
    Mathew, Lijoy K.
    Botbyl, Jeffrey
    Karpinich, Natalie
    Kremer, Brandon E.
    Dhar, Arindam
    Karadimitris, Anastasios
    BLOOD, 2018, 132
  • [40] A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with advanced solid tumours
    Sharma, M.
    Sanborn, R. E.
    Cote, G. M.
    Bendell, J. C.
    Kaul, S.
    Chen, F.
    Berezhnoy, A.
    Moore, P.
    Bonvini, E.
    Sumrow, B. J.
    Luke, J. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S704 - S705
12345